Literature DB >> 8268923

Paternal nondisjunction in trisomy 21: excess of male patients.

M B Petersen1, S E Antonarakis, T J Hassold, S B Freeman, S L Sherman, D Avramopoulos, M Mikkelsen.   

Abstract

Paternal nondisjunction accounts for approximately 5% of cases of trisomy 21. We have studied 36 cases of free trisomy 21, in which the supernumerary chromosome was of paternal origin, with DNA markers in the pericentromeric region and along the long arm of chromosome 21. Fifteen of the paternal cases were consistent with meiosis II errors, 8 with mitotic errors and only 7 with meiosis I nondisjunction. This contrasts markedly with maternally derived trisomy 21, in which meiosis I errors predominate. An excess of males was observed in the meiotic cases (21 males:6 females), highly significantly different from a 1.06 ratio. A significant difference in mean maternal age was found between cases of paternal origin (28.1 years) and those of maternal origin (31.8 years, n = 429). This indicates that the maternal age effect is confined to maternal nondisjunction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8268923     DOI: 10.1093/hmg/2.10.1691

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

1.  On the paternal origin of trisomy 21 Down syndrome.

Authors:  Maj A Hultén; Suketu D Patel; Magnus Westgren; Nikos Papadogiannakis; Anna Maria Jonsson; Jon Jonasson; Erik Iwarsson
Journal:  Mol Cytogenet       Date:  2010-02-23       Impact factor: 2.009

2.  The National Down Syndrome Project: design and implementation.

Authors:  Sallie B Freeman; Emily G Allen; Cindy L Oxford-Wright; Stuart W Tinker; Charlotte Druschel; Charlotte A Hobbs; Leslie A O'Leary; Paul A Romitti; Marjorie H Royle; Claudine P Torfs; Stephanie L Sherman
Journal:  Public Health Rep       Date:  2007 Jan-Feb       Impact factor: 2.792

3.  Parental-age effects in Down syndrome.

Authors:  Santhosh Girirajan
Journal:  J Genet       Date:  2009-04       Impact factor: 1.166

4.  Sex ratio in normal and disomic sperm: evidence that the extra chromosome 21 preferentially segregates with the Y chromosome.

Authors:  D K Griffin; M A Abruzzo; E A Millie; E Feingold; T J Hassold
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

5.  Cytogenetic and epidemiological findings in Down syndrome, England and Wales 1989 to 1993. National Down Syndrome Cytogenetic Register and the Association of Clinical Cytogeneticists.

Authors:  D Mutton; E Alberman; E B Hook
Journal:  J Med Genet       Date:  1996-05       Impact factor: 6.318

6.  The human sex ratio from conception to birth.

Authors:  Steven Hecht Orzack; J William Stubblefield; Viatcheslav R Akmaev; Pere Colls; Santiago Munné; Thomas Scholl; David Steinsaltz; James E Zuckerman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

7.  Chromosomal drive and the evolution of meiotic nondisjunction and trisomy in humans.

Authors:  T Day; P D Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  Investigation of factors associated with paternal nondisjunction of chromosome 21.

Authors:  Tiffany Renee Oliver; Archit Bhise; Eleanor Feingold; Stuart Tinker; Nirupama Masse; Stephanie L Sherman
Journal:  Am J Med Genet A       Date:  2009-08       Impact factor: 2.802

9.  Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects.

Authors:  Emily Graves Allen; Sallie B Freeman; Charlotte Druschel; Charlotte A Hobbs; Leslie A O'Leary; Paul A Romitti; Marjorie H Royle; Claudine P Torfs; Stephanie L Sherman
Journal:  Hum Genet       Date:  2008-12-03       Impact factor: 4.132

10.  Germ-line transmission of trisomy 21: Data from 80 families suggest an implication of grandmaternal age and a high frequency of female-specific trisomy rescue.

Authors:  Natalia V Kovaleva
Journal:  Mol Cytogenet       Date:  2010-03-18       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.